Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
InChiKey: DYGBNAYFDZEYBA-UHFFFAOYSA-N
an Effective Constituent of Ligustrum lucidum Ait
54(4):352-4
Chemical Name: (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid
31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24/h2-16H
TAK-285 Size:Solid 10 mg InChiKey: DYGBNAYFDZEYBA-UHFFFAOYSA-NTAK 285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK 285 is currently being developed by Takeda. TAK 285 was found to be well tolerate in Phase I trials. Absorption of TAK 285 was rapid after oral dosing, and plasma exposure at steady state increased in a dose proportional fashion for doses ranging from 50 to 300 mg b. i. d. A partial response was observed
US$ 14.95
US$ 19.95
US$ 16.99
US$ 18.00